Observational studyAllergy2025
Omalizumab reduces anaphylactic reactions and allows food introduction in food-allergic in children with severe asthma: An observational study.
Observational study in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06316414 (Effects of Omalizumab on Food Allergy in Children With Severe Asthma), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Omalizumab on Food Allergy in Children With Severe Asthma: A Real Life Study
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of omalizumab for IgE-mediated food allergy in children and young adults.Frontiers in immunology · 2025Pooled it
- Update on biologic and small molecules treatments in pediatric allergic diseases.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- Novelties in the pragmatic management of anaphylaxis in pediatric age.European journal of pediatrics · 2026Review
- Real-life lessons on omalizumab and food allergy: The potential for unexplored outcomes.The World Allergy Organization journal · 2026Review
- Clinical remission in allergy and clinical immunology practice: State of the art and World Allergy Organization (WAO) call to action.The World Allergy Organization journal · 2026Review
- Wheat Allergy in the Era of Precision Medicine: From Novel Molecular Markers to New Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Omalizumab for severe IgE-mediated food allergy and severe asthma after pediatric liver transplantation: a case report.Frontiers in pediatrics · 2026Article
- Unveiling Interleukin-40: A Novel Regulator of Macrophage and B Cell Function in Allergic Asthma.International journal of biological sciences · 2026Article
- Off-label applications of omalizumab: Current insights and perspectives.The World Allergy Organization journal · 2025Review
- Biologic Therapies and Quality of Life in Pediatric Patients with Asthma: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Using Biologics in the Prevention of Anaphylaxis.Current allergy and asthma reports · 2025Review
- A World Allergy Organization (WAO) manifesto for the worldwide approval of biologic therapies for food allergy.The World Allergy Organization journal · 2025Article
- Successful Oral Immunotherapy (OIT) Due to Anti-IgE Protection.Journal of clinical medicine · 2025Article
- The Expanding Role of Omalizumab: From Food Allergy to Drug Desensitization.International journal of molecular sciences · 2025Review
- Biologics in IgE-mediated food allergy: A systematic review and meta-analysis of interventional studies.The World Allergy Organization journal · 2025Review
- Omalizumab in Food Allergy in Children: Current Evidence and Future Perspectives.Life (Basel, Switzerland) · 2025Review
- Observational
- Severe Asthma in School-Age Children: An Updated Appraisal on Biological Options and Challenges in This Age Group.Children (Basel, Switzerland) · 2025Review
- Linking IgE and mast cells in pediatric allergic multimorbidity: omalizumab as a therapeutic strategy for asthma and cow's milk allergy.Central-European journal of immunology · 2025Article
- How to manage asthma in a food-allergic patient: A practical approach.Journal of food allergy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundIn Europe, Omalizumab (anti-IgE) is indicated for the treatment of moderate to severe asthma, but not for IgE-mediated food allergy (FA).
objectiveWe assessed the impact of Omalizumab on efficacy, safety, and quality of life (FA-QoL) in patients with moderate to severe asthma and who have a history of anaphylaxis to peanut, tree nuts, fish, egg, milk, and/or wheat.
methodsFood-allergic children (6-18 years) with moderate to severe asthma underwent oral food challenges (OFCs) to establish the threshold of reaction to the culprit food(s) at baseline (T0) and at 4-month intervals (T1, T2, and T3) during their first year of treatment with Omalizumab. We recorded the number and severity of food-allergic reactions, Asthma Control Test (ACT) scores, FA-QoL, and total IgE levels.
resultsIn 65 patients allergic to 107 foods, the No Observed Adverse Events Level (NOAEL) at T1 increased: 243- and 488-fold for fresh and baked milk, respectively; 172- and 134-fold for raw and baked egg; 245-fold for hazelnut; 55-fold for peanut; 31-fold for wheat; and 10-fold for fish. Full tolerance was achieved in 66.4% of OFCs at T1, 58.3% at T2, and 75% at T3. Ninety-five foods were liberalized in the diet of 55 patients; the remaining 12 were introduced by 10 patients at least in traces. Throughout the study, 40 out of 65 were able to get a free diet. ACT increased from 17 (Q1-Q3: 15-17) to 23.6 (Q1-Q3: 23-25). The FA-QoL score in children ≤12 years decreased from 4.63 ± 0.74 to 2.02 ± 1.13, and in adolescents from 4.68 ± 0.92 to 1.90 ± 1.50.
conclusionsDuring Omalizumab therapy, a safe reintroduction of allergenic foods is feasible. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, NCT06316414.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.